LY2228820 dimesylate - CAS 862507-23-1
Catalog number: B0084-286454
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C24H29FN6·2CH4O3S
Molecular Weight:
612.74
COA:
Inquire
Targets:
p38 MAPK
Description:
LY2228820 dimesylate is a highly selective small molecule inhibitor of p38α(IC50=7 nM) and p38β mitogen-activated protein kinases (MAPKs).
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-286454 10 mg $198 In stock
Bulk Inquiry
Purity:
>98%
Synonyms:
LY2228820 dimesylate; LY 2228820 dimesylate; LY-2228820 dimesylate
MSDS:
Inquire
InChIKey:
NARMJPIBAXVUIE-UHFFFAOYSA-N
InChI:
InChI=1S/C24H29FN6.2CH4O3S/c1-23(2,3)13-31-20-17(28-22(31)26)12-11-16(27-20)19-18(14-7-9-15(25)10-8-14)29-21(30-19)24(4,5)6;2*1-5(2,3)4/h7-12H,13H2,1-6H3,(H2,26,28)(H,29,30);2*1H3,(H,2,3,4)
Canonical SMILES:
CC(C)(C)CN1C2=C(C=CC(=N2)C3=C(N=C(N3)C(C)(C)C)C4=CC=C(C=C4)F)N=C1N.CS(=O)(=O)O.CS(=O)(=O)O
1.A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.
Patnaik A1, Haluska P2, Tolcher AW1, Erlichman C2, Papadopoulos KP1, Lensing JL2, Beeram M1, Molina JR2, Rasco DW1, Arcos RR1, Kelly CS3, Wijayawardana SR4, Zhang X4, Stancato LF4, Bell R4, Shi P4, Kulanthaivel P4, Pitou C5, Mulle LB6, Farrington DL4, Cha Clin Cancer Res. 2016 Mar 1;22(5):1095-102. doi: 10.1158/1078-0432.CCR-15-1718. Epub 2015 Nov 18.
PURPOSE: p38 MAPK regulates the production of cytokines in the tumor microenvironment and enables cancer cells to survive despite oncogenic stress, radiotherapy, chemotherapy, and targeted therapies. Ralimetinib (LY2228820 dimesylate) is a selective small-molecule inhibitor of p38 MAPK. This phase I study aimed to evaluate the safety and tolerability of ralimetinib, as a single agent and in combination with tamoxifen, when administered orally to patients with advanced cancer.
2.LY2228820 dimesylate, a selective inhibitor of p38 mitogen-activated protein kinase, reduces angiogenic endothelial cord formation in vitro and in vivo.
Tate CM1, Blosser W, Wyss L, Evans G, Xue Q, Pan Y, Stancato L. J Biol Chem. 2013 Mar 1;288(9):6743-53. doi: 10.1074/jbc.M112.425553. Epub 2013 Jan 18.
LY2228820 dimesylate is a highly selective small molecule inhibitor of p38α and p38β mitogen-activated protein kinases (MAPKs) that is currently under clinical investigation for human malignancies. p38 MAPK is implicated in a wide range of biological processes, in particular those that support tumorigenesis. One such process, angiogenesis, is required for tumor growth and metastasis, and many new cancer therapies are therefore directed against the tumor vasculature. Using an in vitro co-culture endothelial cord formation assay, a surrogate of angiogenesis, we investigated the role of p38 MAPK in growth factor- and tumor-driven angiogenesis using LY2228820 dimesylate treatment and by shRNA gene knockdown. p38 MAPK was activated in endothelial cells upon growth factor stimulation, with inhibition by LY2228820 dimesylate treatment causing a significant decrease in VEGF-, bFGF-, EGF-, and IL-6-induced endothelial cord formation and an even more dramatic decrease in tumor-driven cord formation.
3.p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications.
Ishitsuka K1, Hideshima T, Neri P, Vallet S, Shiraishi N, Okawa Y, Shen Z, Raje N, Kiziltepe T, Ocio EM, Chauhan D, Tassone P, Munshi N, Campbell RM, Dios AD, Shih C, Starling JJ, Tamura K, Anderson KC. Br J Haematol. 2008 May;141(5):598-606. doi: 10.1111/j.1365-2141.2008.07044.x. Epub 2008 Apr 7.
The interaction between multiple myeloma (MM) cells and the bone marrow (BM) microenvironment induces proliferation and survival of MM cells, as well as osteoclastogenesis. This study investigated the therapeutic potential of novel p38 mitogen-activated protein kinase (p38MAPK) inhibitor LY2228820 (LY) in MM. Although cytotoxicity against MM cell lines was modest, LY significantly enhanced the toxicity of bortezomib by down-regulating bortezomib-induced heat shock protein 27 phosphorylation. LY inhibited interleukin-6 secretion from long term cultured-BM stromal cells and BM mononuclear cells (BMMNCs) derived from MM patients in remission. LY also inhibited macrophage inflammatory protein-1alpha secretion from patient MM cells and BMMNCs as well as normal CD14 positive osteoclast precursor cells. Moreover, LY significantly inhibited in vitro osteoclastogenesis from CD14 positive cells induced by macrophage-colony stimulating factor and soluble receptor activator of nuclear factor-kappaB ligand.
4.Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity.
Campbell RM1, Anderson BD, Brooks NA, Brooks HB, Chan EM, De Dios A, Gilmour R, Graff JR, Jambrina E, Mader M, McCann D, Na S, Parsons SH, Pratt SE, Shih C, Stancato LF, Starling JJ, Tate C, Velasco JA, Wang Y, Ye XS. Mol Cancer Ther. 2014 Feb;13(2):364-74. doi: 10.1158/1535-7163.MCT-13-0513. Epub 2013 Dec 19.
p38α mitogen-activated protein kinase (MAPK) is activated in cancer cells in response to environmental factors, oncogenic stress, radiation, and chemotherapy. p38α MAPK phosphorylates a number of substrates, including MAPKAP-K2 (MK2), and regulates the production of cytokines in the tumor microenvironment, such as TNF-α, interleukin-1β (IL-1β), IL-6, and CXCL8 (IL-8). p38α MAPK is highly expressed in human cancers and may play a role in tumor growth, invasion, metastasis, and drug resistance. LY2228820 dimesylate (hereafter LY2228820), a trisubstituted imidazole derivative, is a potent and selective, ATP-competitive inhibitor of the α- and β-isoforms of p38 MAPK in vitro (IC(50) = 5.3 and 3.2 nmol/L, respectively). In cell-based assays, LY2228820 potently and selectively inhibited phosphorylation of MK2 (Thr334) in anisomycin-stimulated HeLa cells (at 9.8 nmol/L by Western blot analysis) and anisomycin-induced mouse RAW264.7 macrophages (IC(50) = 35.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related p38 MAPK Products


CAS 745833-23-2 VX-702

VX-702
(CAS: 745833-23-2)

VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β.

BMS582949
(CAS: 623152-17-0)

BMS582949 is a potent and selective P38 mitogen-activated protein kinase (P38 MAPK) inhibitor with IC50 value of 13nM, which plays a crucial role in regulating ...

AMG 548
(CAS: 864249-60-5)

AMG-548 is a selective p38α inhibitor with Ki value of 0.5nM. It displays >1000-fold selectivity against 36 other kinases, and it can inhibit whole blood LPS-st...

RPR-200765A Mesylayte
(CAS: 218162-38-0)

RPR-200765A Mesylayte, a potent and selective inhibitor of p38 MAP kinase (IC50 = 50 nM), could exhibit a profile of disease modifying activity in rheumatoid ar...

CAS 869185-85-3 SB 203580 hydrochloride

SB 203580 hydrochloride
(CAS: 869185-85-3)

SB 203580 hydrochloride is a water-soluble form of the potent MAP kinase inhibitor SB 203580. It is a selective inhibitor of p38 mitogen-activated protein kinas...

CAS 72873-74-6 SKF-86002

SKF-86002
(CAS: 72873-74-6)

SKF-86002 is a p38 MAP kinase inhibitor, the IC50 is 0.1 - 1 μM. It potently inhibits LPS-induced IL-1 and TNF-α production in human monocytes, the IC50 is1 μM....

CAS 1057394-06-5 AL 8697

AL 8697
(CAS: 1057394-06-5)

AL 8697 is an effective and selective p38α inhibitor and has been found to exhibit some antiinflammatory activities.

CAS 193551-21-2 SB239063

SB239063
(CAS: 193551-21-2)

SB239063 is a potent p38MAPK inhibitor. SB 239063 had an IC(50) of 44 nM for inhibition of recombinant purified human p38alpha. In lipopolysaccharide-stimulated...

Chemical Structure

CAS 862507-23-1 LY2228820 dimesylate

Quick Inquiry

Verification code

Featured Items